The Upstream/Downstream Decision
Process development in biologics splits into upstream (cell culture, fermentation) and downstream (purification, formulation). Some companies hire a single Head of PD who covers both. Others split the roles.
For standard monoclonal antibodies, a single leader can often cover both domains. For complex modalities like bispecifics, ADCs, or fusion proteins, the purification challenges are sufficiently distinct that a downstream specialist at the leadership level adds significant value.
The Scale-Up Mindset
The critical differentiator between a good and a great Head of PD is whether they think about manufacturing from day one.
Many PD scientists optimise processes for the bench. The best PD leaders design processes for the factory. They choose cell lines with commercial-scale productivity in mind. They develop purification schemes that will work in existing facility infrastructure. They anticipate the questions that MSAT teams will ask during technology transfer and build the answers into the development data package.
This mindset comes from experience translating processes from development to manufacturing - and preferably from having been on the receiving end of a difficult technology transfer.
Compensation and Competition
Head of Process Development roles in US biologics companies range from $200,000 to $280,000 base with total compensation of $260,000 to $380,000. The talent pool is reasonably deep for standard mAb processes but thins dramatically for complex modalities. Candidates with bispecific, ADC, or cell therapy PD experience command premiums of 15-20%.
Red Flags in PD Leadership Candidates
1. Single-scale experience. If their entire PD career has been at bench or pilot scale, they may lack the perspective needed to lead commercial-scale process development.
2. Platform dependency. Candidates who cannot explain why they chose specific process parameters, and instead describe following established platform approaches, are likely to struggle with novel molecules that do not fit the platform.